Sun Pharma’s near-term fortunes are tied to the outcome of U.S. FDA’s inspection of its Halol plant.
Here’s why brokerages are still bullish on Fortis despite the founder troubles.
Half of the Nifty50 stocks reported earnings that were in-line with analyst expectations.
The inspection was done due to multiple recall of product recall of a drug in 2017 and issues of stability failure.
Allegation of stock price manipulation “completely baseless and factually incorrect,” Vakrangee says.
The inclusion of ICICI Bank in the model porfolio comes on the back of removing Indonesian Bank BCA.
The third quarter earnings season is set to kickstart on Thursday, with IndusInd Bank and Tata Consultancy Services.
Credit Suisse doesn’t expect any sharp and prolonged correction in Indian equities on the back of strong fund flows.
CLSA’s two key themes and top stock bets for 2018.
BloombergQuint picks five companies from the top 500 companies that were among the best performers.
FII ownership in Nifty stocks declined over the September quarter, while DIIs saw a surge
Balkrishna Industries has surged past analyst expectations as investors bet on its industry-beating margins.
Here are the top picks of Macquarie in the Indian pharma segment...
Cipla expects the U.S. market to contribute about a quarter of its total sales in the next 3-5 years.
Lupin Ltd.’s promoters have been on a shopping spree….17 days in a row.
Shalby Hospitals will use the funds raised for debt repayment and buying equipment.
The U.S. drug regulator made seven observations for Glenmark Pharamceuticals’ Baddi unit.
Investors were better off investing in stocks compared to Nifty in last 9 years.
Vakrangee’s market cap is now bigger than that of Idea Cellular or Power Finance Corporation.
Rs 500 crore deal to help Eris Lifesciences strengthen its position in the CNS (Central Nervous System) segment.
This earnings season has been the best for India’s top companies in at least five quarters.